Allopurinol

Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Retrieved on: 
Wednesday, May 15, 2024
Amyloidosis, Doxycycline, HIV, NDA, FDA, Vaccination, CRL, New Drug Application, Bangladesh Technical Education Board, Gout, Infection, Erythema, Mustang, Fortification, Inflammation, Fortress Biotech, Hyperuricemia, AstraZeneca, IGA, Disease, Allopurinol, Food, Red, Dotinurad, Safety, Liver transplantation, Carcinoma, Cytomegalovirus, CMV, Minocycline, CKPT, Patient, Exercise, Radiation, PDUFA, Dermatology, Menkes disease, Rosacea, Mortality, BLA, URAT1, Pharmaceutical industry

MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024.

Key Points: 
  • In January 2024, Fortress raised gross proceeds of approximately $11.0 million in a registered direct offering priced at-the-market under Nasdaq rules.
  • Fortress’ consolidated net revenue totaled $13.0 million for the first quarter ended March 31, 2024, all of which was generated from our marketed dermatology products.
  • Consolidated research and development expenses including license acquisitions totaled $24.8 million for the first quarter ended March 31, 2024, compared to $39.5 million for the first quarter ended March 31, 2023.
  • Consolidated selling, general and administrative costs were $17.9 million for the first quarter ended March 31, 2024, compared to $25.3 million for the first quarter ended March 31, 2023.

Atom Bioscience Enrolling Patients in US as Part of a Global Phase 2b/3 Clinical Trial of a New Investigational Treatment for Chronic Gout

Retrieved on: 
Wednesday, April 24, 2024
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Part, Inflammatory arthritis, URAT1, Probability, Safety, Kidney failure, Allopurinol, Hyperuricemia, Patient, Gout, Liver, DSM-IV codes, SUA, Quality of life, Pharmaceutical industry

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical trial of ABP-671, a novel investigational orally administered URAT1 inhibitor, for the treatment of chronic gout.

Key Points: 
  • Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical trial of ABP-671, a novel investigational orally administered URAT1 inhibitor, for the treatment of chronic gout.
  • The multicenter, randomized, double-blind trial will enroll 580 patients worldwide.
  • It is caused by long-term hyperuricemia, an excessive concentration of serum uric acid (sUA) greater than 7 mg/dL (420 μmol/L).
  • Gout seriously affects people's quality of life and can increase the probability of sudden cardiac death.

DRESS Smarter: Bridging the Gap in Severe Drug Reactions

Retrieved on: 
Wednesday, July 12, 2023
Knowledge, Hypersensitivity, Eosinophilia, Ohio State University, Disulfiram-like drug, Vancomycin, Heart, Anticonvulsant, Education, World Down Syndrome Day, Smarter Sentencing Act, Fever, Trimethoprim/sulfamethoxazole, Human, Research, Drug reaction with eosinophilia and systemic symptoms, Allopurinol, Rash, Plasma protein binding, DRESS, Patient, Physician, Risk, Ohio State University Wexner Medical Center, REDRESS, Liver, Diagnosis, Health, Recurrence, Lymphadenopathy, Residential care, Pharmaceutical industry, Nursing, Medical device, Vaccine, Lamotrigine

RICHMOND, Va., July 12, 2023 /PRNewswire-PRWeb/ -- Around the world, millions of people suffer from severe adverse drug reactions, many of which do not get proper funding or research. For patients with DRESS Syndrome, the experience can be isolating. However, a nonprofit behind National DRESS Syndrome Day is providing a platform for building awareness of this debilitating life threatening condition. On July 16, 2023, the DRESS Syndrome Foundation will encourage patients and medical communities to unite over this year's theme: "DRESS/smarter." By recognizing positive advancements in DRESS Syndrome, the holiday gives a voice to this uncommon but life-threatening reaction, and supports research efforts that bridge the gap worldwide.

Key Points: 
  • A national holiday with a global reach, DRESS Syndrome Day highlights progress and future insights into severe adverse drug reactions.
  • "There is still so much we don't understand about this severe and potentially fatal drug reaction," explains Tasha Tolliver, Executive Director and Co-Founder of DRESS Syndrome Foundation.
  • Additionally, Dr. Korman's team identified a unique "earlobe crease sign" that distinguishes DRESS from other severe adverse drug reactions, facilitating faster and more accurate diagnosis.
  • "We founded the DRESS Syndrome Foundation to fill a much-needed gap in patient advocacy, a gap that today would have saved our daughters lives," says Nancy Szakacsy, Co-Founder of DRESS Syndrome Foundation.

Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout

Retrieved on: 
Monday, March 21, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Urine, Risk, Obesity, Allopurinol, SUA, Therapy, Fatty liver disease, List of life sciences, University of Alabama, Hepatotoxicity, Chugai Pharmaceutical Co., Kidney, Gout, Uric acid, Tenderness, Nephrotoxicity, Cardiovascular disease, Pain, Joint, Febuxostat, NASH, Safety, Red, Diabetes, Medication, American College, Time, Inflammatory arthritis, Lists of diseases, Sudden death, Degenerative disease, URAT1, American College of Rheumatology, Swelling, FDA, Blood, Division, University, Patient, Pharmaceutical industry, Copper, Hyperuricemia, Rheumatology

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the results of a randomized double-blind, placebo-controlled Phase 2a clinical trial of ABP-671 to treat chronic gout.

Key Points: 
  • Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the results of a randomized double-blind, placebo-controlled Phase 2a clinical trial of ABP-671 to treat chronic gout.
  • These results demonstrate that ABP-671, our investigational drug for the treatment of gout, lowers uric acid levels considerably, which is a major step forward for the control of chronic gout.
  • I am very excited by these results, said Atom CEO, Chairman, and Founder Dr. William Shi.
  • The poor efficacy and safety profiles of available gout drugs creates significant unmet clinical demand for patients suffering from chronic gout.

Tumor Lysis Syndrome (TLS) Market Spotlight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022
Health, Oncology, Burkitt lymphoma, Incidence, Sanofi, Acute leukemia, Probability, Tumor lysis syndrome, Acute myeloid leukemia, TLS, Febuxostat, Pharmaceutical industry, Allopurinol

The "Market Spotlight: Tumor Lysis Syndrome (TLS)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Tumor Lysis Syndrome (TLS)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed drugs, clinical trials, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
  • The publisher estimates that in 2017, there were approximately 12,400 incident cases of tumor lysis syndrome (TLS) worldwide among individuals with high-risk malignancies (acute myeloid leukemia, acute lymphocytic leukemia, and Burkitt's lymphoma)
    The number of incident cases is forecast to increase to 13,600 by 2026.
  • Sanofi has carried out the most clinical trials in the TLS space, with Menarini being the only other trial sponsor.

Wormington and Bollinger files Lawsuit alleging SJS and TEN are caused by a drug distributed by Prometheus Laboratories, Inc

Retrieved on: 
Tuesday, November 19, 2019
RTT, Drug eruptions, Drugs, Hepatotoxins, Organ systems, Medicine, Stevens–Johnson syndrome, Allopurinol, Toxic epidermal necrolysis, Severe cutaneous adverse reactions, Erythema multiforme major

This prescription medication is made and marketed by the San Diego-based pharmaceutical company, Prometheus.

Key Points: 
  • This prescription medication is made and marketed by the San Diego-based pharmaceutical company, Prometheus.
  • Plaintiff alleges in the lawsuit that Prometheus failed to fully warn consumers and physicians of the harmful side effects of Zyloprim, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Plaintiff's Complaint alleges that SJS and TEN are extremely serious conditions that are often times fatal or result in catastrophic permanent injuries.
  • Allopurinol is a known cause of SJS and TEN, yet Prometheus failed to warn consumers of important information concerning this potential side effect.

Allopurinol (CAS 315-30-0) Market Research Report, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 4, 2019
Health, Pharmaceutical, RTT, Allopurinol, Hepatotoxins, Market research, Drugs

The "Allopurinol (CAS 315-30-0) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Allopurinol (CAS 315-30-0) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.
  • This report is a result of industry experts' diligent work on researching the world market of Allopurinol.
  • The report helps to build up a clear view of the market (trends and prospects), identify major players in the industry, and estimate main downstream sectors.